Cybin Provides Corporate Update On Upcoming Clinical Milestones; Initiation Of Pivotal CYB003 Phase 3 Study In Major Depressive Disorder Expected Imminently; 12-Month Efficacy Data From Phase 2 Study Of CYB003 In MDD Expected In Early Q4 2024; Phase 2 Topline Efficacy And Safety Results For CYB004 In Generalized Anxiety Disorder Expected Year-End 2024 Or Early Q1 2025
Portfolio Pulse from Benzinga Newsdesk
Cybin Inc. is set to initiate a pivotal Phase 3 study for CYB003 in Major Depressive Disorder imminently, with 12-month efficacy data from its Phase 2 study expected in early Q4 2024. Additionally, Phase 2 results for CYB004 in Generalized Anxiety Disorder are anticipated by the end of 2024 or early 2025. The company has strengthened its R&D team with new leadership.
September 19, 2024 | 9:40 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cybin Inc. is advancing its clinical trials with the imminent start of a Phase 3 study for CYB003 in MDD and upcoming data releases for CYB003 and CYB004. The company has also bolstered its R&D team, which may positively influence its stock price.
The initiation of a pivotal Phase 3 study and upcoming data releases are significant milestones that could positively impact Cybin's stock price. The strengthening of the R&D team further supports potential positive outcomes.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100